HEK293T cells (6X10 3 ) were seeded in 96-well plates. On the next day, cells were transfected with combinations of the Gluc1 plasmid encoding an ETS protein and a Gluc2 plasmid encoding either MR (C) or ERα (D). Twenty-four hours later, cells were starved overnight for serum factors and thereafter they were treated for 60 minutes with vehicle, DEX (1 μM) or estradiol (E2; 10 nM). Cells were then lysed and luminescence was determined. The bar plot shows the fold changes in luciferase activity in response to DEX or E2 (as compared to vehicle-treated cells) for each set of interactions between an ETS family TF and a steroid hormone receptor.
Luminescence of treated cells was normalized to vehicle-treated cells. *, p<0.05. (E) HEK293T cells were co-transfected with Gluc1-ERα and GR-Gluc2. Twenty-four hours later, cells were treated for 60 minutes with either vehicle, DEX (1 μM) or estradiol (10 nM). Luminescence of extracted cells was determined in biological duplicates and normalized to cells treated with vehicle only. *, p≤0.05; ns, not significant. Likewise, individual domains of GR were inserted N-terminally to Gluc2. HEK293T cells (6X10 3 ) were co-transfected with the Gluc1 plasmid encoding different domains of FLI1 and the Gluc2 plasmid encoding full length GR. Alternatively, we used the Gluc2 plasmid encoding different domains of GR, and the Gluc1 plasmid encoding full length FLI1. After 24 hours, cells were starved overnight and then treated for 60 minutes with vehicle or with DEX (1 M).
Supplementary
Luminescence was determined in biological triplicates. The bar plots show the normalized fold changes in luciferase activity induced by DEX. *, p ≤ 0.05; **, p ≤ 0.01. (C and D) HEK293T cells were transfected with Gluc1 plasmids encoding different FLI1 domains (C), or Gluc2 plasmids encoding GR domains (D). Gluc proteins were immunoprecipitated (IP) using a specific antibody. Immunoblotting (IB) was performed using antibodies that detected the endogenous forms of GR or FLI1. Blots are representative of three or more biological replicates.
Two different antibodies to GR were used. The lowermost panels present immunoblots of whole cell extracts (no prior IP) blotted for the respective endogenous protein, either GR (C) or FLI1 genes in FLI1-depleted Ewing sarcoma cells. A673 cells grown in 90-mm dishes were transfected in triplicates with siRNA oligonucleotides specific to FLI1, or with control oligonucleotides. Forty-eight hours later, cells were harvested and processed for RNA isolation, which was followed by sequencing. Fold-change differences were plotted against statistical significance. Note the location of the FLI1 gene (in green; see Supplementary Table S3 ). Figure 6A were extracted and analyzed using immunoblotting with the indicated antibodies. (B) Whole extracts prepared from the tumors presented in Figure 6D were analyzed using immunoblotting with the indicated antibodies. Note that tumors from three different mice per group were analyzed. Figure S6 (related to Figures 4 and 5) Supplementary Figure S7 (related to Figures 1, 3, 4 Figures: 1D, 1G, 3B, 4A, 4B, 4E, 5C, 2SC and 2SD, respectively.

Supplementary Tables
No. Gene
Accession Number X-GLuc1 Supplementary Table S1 : List of all constructs generated for PCA (related to Figure 1) .
X-GLuc2
Listed are seventeen cDNAs encoding either nuclear receptors (fused to the 5' end of Gluc2) or ETS family members (fused to the 3' end of Gluc1). The respective human genome accession numbers are indicated. TGGTGGGTCCTCCGGAGAC GGG ACT ATT AAG GAG GCT CTG TCG  FLI1-Rev  AAACGGGCCCTCTAGACTA GTA GTA GCT GCC TAA GTG TGA AGG C  ELK3-Fw  TGGTGGGTCCTCCGGAGAG AGT GCA ATC ACG CTG TGG C  ELK3-Rev  AAACGGGCCCTCTAGATCA GGA TTT CTG AGA GTT TGA AGA AAG  CAG TAC  ERG-Fw  TGGTGGGTCCTCCGGAATT CAG ACT GTC CCG GAC CCA GC  ERG-Rev  AAACGGGCCCTCTAGATTA GTA GTA AGT GCC CAG ATG AGA AGG  CA  ELF3-Fw  TGGTGGGTCCTCCGGAGCT GCA ACC TGT GAG ATT AGC Supplementary Table S2 : List of all primers used for cloning and validation (related to Figure 1) . Fw, forward primer; Rev, reverse primer. ATP2B1  HHIPL2  S100A13  H2AFY2  BEND2  ID1  S100A16  HMGB1  BST1  IGFBP3  S100A2  HOOK1  C15orf48  IGFBP5  S100A4  IRS2  CALD1  IGFBP7  S100A5  KLHL23  CCL2  IL18  S100A6  LBH  CCL5  IL6  S1PR3  MCM4  CD44  ITPR2  SEC14L2  MYOM2  CDH13  KANK2  SERPINE1  NR0B1  CFI  KYNU  SH3BP5  OTX2  CH25H  L1CAM  SH3KBP1  PRKCB  CHI3L1  LAMA4  SIX1  SLAIN1  CLDN11  LAMC1  SMAD3  SLC5A6  COL12A1  LGALS3  SRGN  TRAV1-2  COL1A1  LOX  SYNJ2  UGT3A2  COL1A2  LOXL2  TAGLN  YPEL5  COL3A1  LRRC17  TFPI2  OTX2  COL4A1  MDGA2  TGFB2  PRKCB  COL6A1  MEST  TGFB2-OT1  SLAIN1  CPA4  MGP  TGFBI  SLC5A6  CREB3L1  MIR21  TGFBR2  TRAV1-2  CRYAB  MIR503  TIMP2  UGT3A2  CSF2  MIR503HG  TM4SF1  YPEL5  CTGF  MLPH  TMEM200A  CTSB  MRPS6  TMSB4X  CTSO  MYL6  TNFSF18  CXCL1  NAMPT  TPM1  CXCL6  NAV3  TRHR  CYP1B1  NT5E  UGCG  CYR61  P4HA2  VCAM1  DCBLD2  PDP1  VEGFC  DISP2  PENK  VIM  DKK1  PHLDA1  ZFP36L1  DKK3 PHLDB2 ZFP36L2 DST Supplementary Table S3 : List of down-or up-regulated genes in FLI1-depleted Ewing sarcoma cells (related to Supplementary Figure S3 ). A673 cells grown in 90-mm dishes were transfected in triplicates with siRNA oligonucleotides specific to FLI1, or with control oligonucleotides. Forty-eight hours later, cells were harvested and RNA was isolated and sequenced.
Gluc1-ETS primers
PU.1-Fw TGGTGGGTCCTCCGGATTACAGGCGTGCAAAATGGAAGGG PU.1-Rev AAACGGGCCCTCTAGATCAGTGGGGCGGGTGGC FLI1-Fw
Downregulated genes Upregulated genes
AC016612.1 ABI3BP EIF3J-AS1 PLAT AL365440.1 AC008938.1 ENC1 PLAU AL844908.1 AC025857.2 EPGN PLK2 AP000924.1 AC099673.1 EREG PODXL CALM1 ACTA2 ERRFI1 PPFIBP1 CD83 ADGRF5 EVA1A PRSS23 CLDN1 ADGRG1 F3 PTGR1 CNTNAP2 ADM FBN1 PTX3 CXCL10 AL050341.1 FCRL1 RAI14 DNAL4 ANKRD1 FN1 RHBDL2 FAM19A5 AP000753.1 FNDC3B RN7SL125P FAM84B AREG FOSL2 RNU6-1092P FDX1 ARHGAP29 GNAI1 RUNX2 FEZF1 ATP1B1 GPC6 S100A10 FEZF1-AS1
